Human integumentary system-focussed personal healthcare company Integumen announced on Monday that it had received orders from La Prairie, Merck & Co., and Galderma.
The AIM-traded firm said it had first received orders from Swiss-based beauty company La Prairie, for Integumen to conduct efficacy trials using its 'Labskin' product as the platform, which would test certain materials in La Prairie's range of products.
Its board described Labskin as a "three-dimensional human skin equivalent" (HSE) model that resembled the discrete biological layers found in human skin.
Since the EU ban on testing of cosmetics on animals, the company believed it was "ideally positioned" to take advantage of the fact that HSEs were being increasingly used by developers operating in the dermatology space, such as La Prairie.
The second order, from international developer, manufacturer and distributor of pharmaceuticals Merck, was an evaluation order with Integumen - also for the company's Labskin HSE model.
Its third order announced on Monday was from dermatological treatment specialist Galderma, a subsidiary of Nestlé.
Galderma also ordered Labskin for the testing of materials and formulations in their headquarters in Lausanne, Switzerland.
"We are delighted to receive these orders from such reputable blue chip clients," said Integumen CEO Declan Service.
"With an ever-increasing focus on the human microbiome, Labskin's advantage of being able to host bacteria in a similar environment to that of human skin is proving to be an attractive option for companies focussed on R&D in skincare."
Service said that, while relatively small in revenue terms, the three orders both demonstrated the company's ability to commercialise its products and technologies, and its ability to build relationships with established companies.
"In addition, we have secured our first order for Labskin under the three-year OEM supply agreement we signed with our partner in Germany, all of which is testament to the hard work our sales and marketing team continues to do."